BRPI0914969A2 - método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas - Google Patents

método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas

Info

Publication number
BRPI0914969A2
BRPI0914969A2 BRPI0914969A BRPI0914969A BRPI0914969A2 BR PI0914969 A2 BRPI0914969 A2 BR PI0914969A2 BR PI0914969 A BRPI0914969 A BR PI0914969A BR PI0914969 A BRPI0914969 A BR PI0914969A BR PI0914969 A2 BRPI0914969 A2 BR PI0914969A2
Authority
BR
Brazil
Prior art keywords
her2 receptor
cancers expressing
truncated variants
diagnosing cancers
diagnosing
Prior art date
Application number
BRPI0914969A
Other languages
English (en)
Inventor
Joaquín Arribas López
Josep Lluis Parra Palau
José Baselga Torres
Kim Pedersen
Pier-Davide Angellini
Sirle Laos
Original Assignee
Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Fundació Privada Inst D Investigació Oncológica De Vall Hebron
Fundació Privada Inst De Recerca Hospital Uni Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institució Catalana De Recerca I Estudis Avancats, Fundació Privada Inst D Investigació Oncológica De Vall Hebron, Fundació Privada Inst De Recerca Hospital Uni Vall Hebron filed Critical Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Publication of BRPI0914969A2 publication Critical patent/BRPI0914969A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
BRPI0914969A 2008-06-02 2009-06-05 método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas BRPI0914969A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200801652A ES2342646B1 (es) 2008-06-02 2008-06-02 Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
PCT/EP2009/056976 WO2010000565A1 (en) 2008-06-02 2009-06-05 Method for diagnosing cancers expressing the her2 receptor or its truncated variants

Publications (1)

Publication Number Publication Date
BRPI0914969A2 true BRPI0914969A2 (pt) 2015-10-20

Family

ID=40911029

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914969A BRPI0914969A2 (pt) 2008-06-02 2009-06-05 método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas

Country Status (21)

Country Link
US (1) US8389227B2 (pt)
EP (1) EP2293819B1 (pt)
JP (2) JP5753079B2 (pt)
KR (2) KR20160140974A (pt)
CN (1) CN102202692B (pt)
AU (2) AU2009265921B2 (pt)
BR (1) BRPI0914969A2 (pt)
CA (1) CA2727365A1 (pt)
CY (1) CY1115798T1 (pt)
DK (1) DK2293819T3 (pt)
EA (1) EA025218B1 (pt)
ES (2) ES2342646B1 (pt)
HK (1) HK1157658A1 (pt)
HR (1) HRP20141158T1 (pt)
IL (1) IL209769A (pt)
MX (1) MX2010013419A (pt)
PL (1) PL2293819T3 (pt)
PT (1) PT2293819E (pt)
SI (1) SI2293819T1 (pt)
WO (1) WO2010000565A1 (pt)
ZA (1) ZA201009010B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638598B2 (en) * 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
EP2438442B1 (en) * 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
WO2010083470A1 (en) 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-3
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2330131B1 (en) 2009-12-07 2014-10-08 Fundació Privada Institució Catalana De Recerca I Estudis Avancats Antibodies against HER2 truncated variant CTF-611
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
US20160067307A1 (en) 2013-05-01 2016-03-10 Five Prime Therapeutics, Inc. Methods of treating cancer
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
EP3872090A1 (en) 2014-03-11 2021-09-01 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
KR20240038121A (ko) 2015-05-30 2024-03-22 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
SG11201810032PA (en) * 2016-05-12 2018-12-28 Agency Science Tech & Res Anti-erbb-2 antibodies and uses thereof
ES2897217T3 (es) 2016-09-30 2022-02-28 Hoffmann La Roche Anticuerpos biespecíficos frente a p95HER2
IL267990B2 (en) 2017-01-25 2024-04-01 Molecular Templates Inc Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
WO2021013950A1 (en) 2019-07-23 2021-01-28 Mnemo Therapeutics Immune cells defective for suv39h1
CN110865184B (zh) * 2019-12-04 2023-04-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Srsp蛋白和srsp抗原表位肽的应用及诊断和***的产品
EP3915576A1 (en) 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU3352495A (en) 1994-08-30 1996-03-22 Barbara Ann Spruce Agents for inducing apoptosis and applications of said agents in therapy
ATE253122T1 (de) * 1996-08-14 2003-11-15 Us Gov Health & Human Serv Vektor für polynukleotidimpfstoffe
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
DE60042693D1 (de) * 1999-08-27 2009-09-17 Genentech Inc Dosierung für die behandlung mit anti erbb2-antikörpern
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2342646B1 (es) * 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
EP2438442B1 (en) * 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95

Also Published As

Publication number Publication date
HK1157658A1 (en) 2012-07-06
CN102202692A (zh) 2011-09-28
ES2342646A1 (es) 2010-07-09
CA2727365A1 (en) 2010-01-07
JP2015214546A (ja) 2015-12-03
IL209769A (en) 2016-04-21
IL209769A0 (en) 2011-02-28
EA201001874A1 (ru) 2011-08-30
US8389227B2 (en) 2013-03-05
ES2528132T3 (es) 2015-02-04
AU2009265921B2 (en) 2015-04-02
JP5753079B2 (ja) 2015-07-22
KR20110031187A (ko) 2011-03-24
KR101785117B1 (ko) 2017-11-07
EA025218B1 (ru) 2016-12-30
CY1115798T1 (el) 2017-01-25
MX2010013419A (es) 2011-08-15
ZA201009010B (en) 2012-03-28
US20090311262A1 (en) 2009-12-17
ES2342646B1 (es) 2011-04-26
JP2011525175A (ja) 2011-09-15
SI2293819T1 (sl) 2015-01-30
EP2293819B1 (en) 2014-09-03
DK2293819T3 (en) 2014-12-08
KR20160140974A (ko) 2016-12-07
HRP20141158T1 (hr) 2015-02-13
CN102202692B (zh) 2014-03-12
AU2015202854A1 (en) 2015-06-18
WO2010000565A1 (en) 2010-01-07
AU2009265921A1 (en) 2010-01-07
EP2293819A1 (en) 2011-03-16
PL2293819T3 (pl) 2015-04-30
PT2293819E (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
BRPI0914969A2 (pt) método para diagnóstico de cânceres que expressam o receptor de her2 ou suas variantes truncadas
HK1222397A1 (zh) 診斷抗體測定
BRPI0919256A2 (pt) sistema de diagnóstico de integridade de riser submarino
FR2923957B1 (fr) Unite formant coque de blindage
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0813569A2 (pt) Método de inspeção.
BRPI0921997A2 (pt) dispositivo para medição do componente de sangue.
BRPI0906491A2 (pt) Método para reconstrução de imagem.
BRPI0816624A2 (pt) Sapata de trilho ferroviário
BRPI0906931A2 (pt) Unidade de embalagem para artigos com recursos de abertura
BRPI0921151A2 (pt) técnica para padronização de conteúdo
BRPI0810566A2 (pt) métodos de ativação de transponder
FR2922011B1 (fr) Instrument de secours pour aeronef.
BRPI0914972A2 (pt) instalação de estacionamento para veículos automóveis
CL2008000325S1 (es) Automovil.
CL2008000916S1 (es) Automovil.
ES1062269Y (es) Remolque de arrastre para trabajos de la vendimia
ES1068036Y (es) Dispositivo para la union de dos vigas
ES1065327Y (es) Dispositivo para la union de barandas
ES1069558Y (es) Dispositivo empotrable para la sujecion de elementos de seguridad
ES1062134Y (es) Dispositivo de union para cubitera.
FR2912510B1 (fr) Installation de test.
ES1066265Y (es) Dispositivo para cubrir vallas bionda de guardarrailes
CL2008000073A1 (es) Metodo para obtener rutilio a partir de materiales que contienen minerales ferrotitaniferos.
ES1068024Y (es) Dispositivo de frenado para mosquiteras

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 16/32 (2006.01), G01N 33/574 (2006.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements